You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View
See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.
Latest Blood Glucose Articles
Popular Blood Glucose Articles
Highly Recommended Blood Glucose Articles
French drug maker Sanofi-aventis
French drug maker Sanofi-aventis says that results from a Phase III trial of its experimental type 2 diabetes drug lixisenatide show that the drug successfully lowered patients' blood glucose levels and body weight, but did not increase the risk of hypoglycemia.
Lixisenatide is a GLP-1 agonist, one of a family of drugs that work by stimulating the release of insulin when blood sugar levels rise too high.
The Phase III study tracked 361 type 2 patients with A1C levels between 7% and 10% who were not receiving any therapy for blood glucose. The patients were divided into three groups, two that took once-daily doses of the drug at different levels of strength, and a third that received a placebo. The test lasted 12 weeks.
Sanofi says that the two groups taking the experimental drug experienced "significantly reduced" A1C levels-including levels below 7%-and "significantly improved" fasting plasma glucose and two-hour post-meal glucose.
If lixisenatide gains FDA approval to go to market, it will join a field of GLP-1 agonists that includes Amylin and Eli Lilly's Byetta (exenatide) and Novo Nordisk's Victoza (liraglutide). Financial analysts say the drug could carve out a $500 million niche in the U.S. market.
Categories: A1c Test, Blood Glucose, Byetta, Diabetes, Diabetes, Eli Lilly, FDA, Hypoglycemia Unawareness, Novo Nordisk, Type 2 Issues, Victoza
0 comments -
May 23, 2011
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.




Email to a Friend
Send a link to this page to your friends and colleagues.